文献速递神经免疫

50岁及以上非活动性多发性硬化患者停用高效治疗与继续治疗的比较

High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS.
PubMed 文献 · JAMA Neurol · 2024-01-01

该观察性队列研究基于法国多发性硬化登记数据库,纳入1620例50岁及以上非活动性复发缓解型多发性硬化患者,按1:1倾向评分匹配比较停用与继续高效治疗。停用组首次复发风险显著高于继续组(HR 4.1,95%CI 2.0-8.5,P<.001),其中那他珠单抗和芬戈莫德停药后风险升高,抗CD20治疗停药后无显著升高。

要点

  • 50岁及以上非活动性多发性硬化患者停用高效治疗后首次复发风险显著升高(HR 4.1)。
  • 停用那他珠单抗(HR 7.2)和芬戈莫德(HR 4.5)与复发风险升高相关。
  • 停用抗CD20治疗(HR 1.1)未观察到复发风险显著升高。

核心结论

  • 在50岁及以上非活动性多发性硬化患者中,停用影响免疫细胞运输的高效治疗(那他珠单抗和芬戈莫德)后复发风险显著增加。
  • 停用耗竭B细胞的高效治疗(抗CD20治疗)后复发风险无显著增加。

研究设计与样本

  • 观察性队列研究,使用法国多发性硬化登记数据库(OFSEP)38家转诊中心的数据。
  • 从84704例患者中提取1857例50岁及以上、接受高效治疗且至少2年无复发或磁共振成像活动的复发缓解型多发性硬化患者数据。
  • 经病历核实后,1620例患者被分类为停用或继续高效治疗,并使用动态倾向评分(包括年龄、性别、疾病表型、残疾、所关注治疗及距末次炎症活动时间)进行1:1匹配。
  • 患者纳入时间为2008年2月至2021年11月,平均(标准差)随访5.1(2.9)年,数据提取于2022年6月。

主要发现

  • 1620例纳入患者中,1175例(72.5%)为女性,平均(标准差)年龄54.7(4.8)岁。
  • 在高效治疗继续组1452例和停用组168例中,每组各154例患者经倾向评分匹配(平均[标准差]年龄57.7[5.5]岁;距末次炎症活动平均[标准差]时间5.6[3.8]年;倾向评分匹配后平均[标准差]随访时间2.5[2.1]年)。
  • 停用高效治疗组首次复发时间较继续组显著缩短(风险比4.1;95%CI 2.0-8.5;P<.001)。
  • 不同高效治疗间存在差异:那他珠单抗风险比7.2(95%CI 2.1-24.5;P=.001),芬戈莫德风险比4.5(95%CI 1.3-15.5;P=.02),抗CD20治疗风险比1.1(95%CI 0.3-4.8;P=.85)。

临床怎么用

  • 作者认为,该结果可为临床实践中停用高效治疗的决策提供参考。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: A recent randomized clinical trial concluded that discontinuing medium-efficacy therapy might be a reasonable option for older patients with nonactive multiple sclerosis (MS), but there is a lack of data on discontinuing high-efficacy therapy (HET). In younger patients, the discontinuation of natalizumab and fingolimod is associated with a risk of rebound of disease activity. OBJECTIVE: To determine whether discontinuing HET in patients 50 years and older with nonactive MS is associated with an increased risk of relapse compared with continuing HET. DESIGN, SETTING, AND PARTICIPANTS: This observational cohort study used data from 38 referral centers from the French MS registry (Observatoire Français de la Sclérose en Plaques [OFSEP] database). Among 84704 patients in the database, data were extracted for 1857 patients 50 years and older with relapsing-remitting MS treated by HET and with no relapse or magnetic resonance imaging activity for at least 2 years. After verification of the medical records, 1620 patients were classified as having discontinued HET or having remained taking treatment and were matched 1:1 using a dynamic propensity score (including age, sex, disease phenotype, disability, treatment of interest, and time since last inflammatory activity). Patients were included from February 2008 to November 2021, with a mean (SD) follow-up of 5.1 (2.9) years. Data were extracted in June 2022. EXPOSURES: Natalizumab, fingolimod, rituximab, and ocrelizumab. MAIN OUTCOMES AND MEASURES: Time to first relapse. RESULTS: Of 1620 included patients, 1175 (72.5%) were female, and the mean (SD) age was 54.7 (4.8) years. Among the 1452 in the HET continuation group and 168 in the HET discontinuation group, 154 patients in each group were matched using propensity scores (mean [SD] age, 57.7 [5.5] years; mean [SD] delay since the last inflammatory activity, 5.6 [3.8] years; mean [SD] follow-up duration after propensity score matching, 2.5 [2.1] years). Time to first relapse was significantly reduced in the HET discontinuation group compared with the HET continuation group (hazard ratio, 4.1; 95% CI, 2.0-8.5; P < .001) but differed between HETs, with a hazard ratio of 7.2 (95% CI, 2.1-24.5; P = .001) for natalizumab, 4.5 (95% CI, 1.3-15.5; P = .02) for fingolimod, and 1.1 (95% CI, 0.3-4.8; P = .85) for anti-CD20 therapy. CONCLUSION AND RELEVANCE: As in younger patients, in patients 50 years and older with nonactive MS, the risk of relapse increased significantly after stopping HETs that impact immune cell trafficking (natalizumab and fingolimod). There was no significant increase in risk after stopping HETs that deplete B-cells (anti-CD20 therapy). This result may inform decisions about stopping HETs in clinical practice.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Jouvenot G, Courbon G, Lefort M, et al. High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS. JAMA Neurol. 2024. PMID: 38526462. doi:10.1001/jamaneurol.2024.0395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。